Capricorn Shareholders proposed a cash special dividend expected to be $620 million, equivalent to £1.72/share, immediately prior to Completion of the Capricorn and NewMed Combination. The Combination exchange ratio values Capricorn, on an ex-dividend basis, at $338 million or £0.99/share, a 46% premium to the theoretical ex-dividend price on 28 September 2022 (being the last business day prior to the date of this announcement).